Medtronic receives fda approval for interstim x™ system, the next generation of the most personalized sacral nerve stimulation therapy for bladder and bowel control

Dublin, feb. 22, 2022 /prnewswire/ -- medtronic plc (nyse:mdt), a global leader in healthcare technology, today announced it received approval from the u.s. food and drug administration (fda) for interstim x™ ― the next generation of the interstim™ portfolio's recharge-free device – and it is available immediately. interstim systems are the standard of care in advanced therapy options, and the most personalized system, to deliver sacral neuromodulation (snm) therapy.
MDT Ratings Summary
MDT Quant Ranking